Literature DB >> 9223472

Neutralizing human monoclonal antibodies to conformational epitopes of human T-cell lymphotropic virus type 1 and 2 gp46.

K G Hadlock1, J Rowe, S Perkins, P Bradshaw, G Y Song, C Cheng, J Yang, R Gascon, J Halmos, S M Rehman, M S McGrath, S K Foung.   

Abstract

Ten human monoclonal antibodies derived from peripheral B cells of a patient with human T-cell lymphotropic virus (HTLV)-associated myelopathy are described. One monoclonal antibody recognized a linear epitope within the carboxy-terminal 43 amino acids of HTLV gp21, and two monoclonal antibodies recognized linear epitopes within HTLV type 1 (HTLV-1) gp46. The remaining seven monoclonal antibodies recognized denaturation-sensitive epitopes within HTLV-1 gp46 that were expressed on the surfaces of infected cells. Two of these antibodies also bound to viable HTLV-2 infected cells and immunoprecipitated HTLV-2 gp46. Virus neutralization was determined by syncytium inhibition assays. Eight monoclonal antibodies, including all seven that recognized denaturation-sensitive epitopes within HTLV-1 gp46, possessed significant virus neutralization activity. By competitive inhibition analysis it was determined that these antibodies recognized at least four distinct conformational epitopes within HTLV-1 gp46. These findings indicate the importance of conformational epitopes within HTLV-1 gp46 in mediating a neutralizing antibody response to HTLV infection.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9223472      PMCID: PMC191838     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  68 in total

1.  Generation and characterization of monoclonal antibodies against multiple epitopes on the C-terminal half of envelope gp46 of human T-cell leukemia virus type-I (HTLV-I).

Authors:  Y Tanaka; M Yasumoto; H Nyunoya; T Ogura; M Kikuchi; K Shimotohno; H Shiraki; N Kuroda; H Shida; H Tozawa
Journal:  Int J Cancer       Date:  1990-10-15       Impact factor: 7.396

2.  Determination of a unique and immunodominant epitope of human T cell lymphotropic virus type I.

Authors:  J J Lipka; K Bui; G R Reyes; R Moeckli; S Z Wiktor; W A Blattner; E L Murphy; G M Shaw; C V Hanson; J J Sninsky
Journal:  J Infect Dis       Date:  1990-08       Impact factor: 5.226

3.  Multiple neutralizing B-cell epitopes of human T-cell leukemia virus type 1 (HTLV-1) identified by human monoclonal antibodies. A basis for the design of an HTLV-1 peptide vaccine.

Authors:  E Baba; M Nakamura; Y Tanaka; M Kuroki; Y Itoyama; S Nakano; Y Niho
Journal:  J Immunol       Date:  1993-07-15       Impact factor: 5.422

4.  Spastic ataxia associated with human T-cell lymphotropic virus type II infection.

Authors:  W J Harrington; W Sheremata; B Hjelle; D K Dube; P Bradshaw; S K Foung; S Snodgrass; G Toedter; L Cabral; B Poiesz
Journal:  Ann Neurol       Date:  1993-04       Impact factor: 10.422

5.  Effect of immunization on HTLV-I infection in rabbits.

Authors:  N Takehara; Y Iwahara; Y Uemura; T Sawada; Y Ohtsuki; H Iwai; H Hoshino; I Miyoshi
Journal:  Int J Cancer       Date:  1989-08-15       Impact factor: 7.396

6.  Seroepidemiologic, molecular, and phylogenetic analyses of simian T-cell leukemia viruses (STLV-I) from various naturally infected monkey species from central and western Africa.

Authors:  N K Saksena; V Herve; J P Durand; B Leguenno; O M Diop; J P Digouette; C Mathiot; M C Muller; J L Love; S Dube
Journal:  Virology       Date:  1994-01       Impact factor: 3.616

7.  Native oligomeric human immunodeficiency virus type 1 envelope glycoprotein elicits diverse monoclonal antibody reactivities.

Authors:  P L Earl; C C Broder; D Long; S A Lee; J Peterson; S Chakrabarti; R W Doms; B Moss
Journal:  J Virol       Date:  1994-05       Impact factor: 5.103

8.  Inhibition of human immunodeficiency virus type 1 activity in vitro by oligonucleotides composed entirely of guanosine and thymidine.

Authors:  J Ojwang; A Elbaggari; H B Marshall; K Jayaraman; M S McGrath; R F Rando
Journal:  J Acquir Immune Defic Syndr (1988)       Date:  1994-06

9.  Transmission of HTLV-I by blood transfusion and its prevention by passive immunization in rabbits.

Authors:  R Kataoka; N Takehara; Y Iwahara; T Sawada; Y Ohtsuki; Y Dawei; H Hoshino; I Miyoshi
Journal:  Blood       Date:  1990-10-15       Impact factor: 22.113

10.  Genetic analysis and molecular phylogeny of simian T-cell lymphotropic virus type I: evidence for independent virus evolution in Asia and Africa.

Authors:  K J Song; V R Nerurkar; N Saitou; A Lazo; J R Blakeslee; I Miyoshi; R Yanagihara
Journal:  Virology       Date:  1994-02-15       Impact factor: 3.616

View more
  17 in total

1.  RNA stability regulates human T cell leukemia virus type 1 gene expression in chronically-infected CD4 T cells.

Authors:  Hsin-Ching Lin; Peter J Simon; Riza M Ysla; Steven L Zeichner; Gary Brewer; Arnold B Rabson
Journal:  Virology       Date:  2017-05-04       Impact factor: 3.616

2.  Conformation-specific antibodies targeting the trimer-of-hairpins motif of the human T-cell leukemia virus type 1 transmembrane glycoprotein recognize the viral envelope but fail to neutralize viral entry.

Authors:  Antonis Mirsaliotis; Kulpash Nurkiyanova; Daniel Lamb; Jenny M Woof; David W Brighty
Journal:  J Virol       Date:  2007-03-21       Impact factor: 5.103

3.  Similar regulation of cell surface human T-cell leukemia virus type 1 (HTLV-1) surface binding proteins in cells highly and poorly transduced by HTLV-1-pseudotyped virions.

Authors:  Kathryn S Jones; Manisha Nath; Cari Petrow-Sadowski; Andrea C Baines; Megan Dambach; Ying Huang; Francis W Ruscetti
Journal:  J Virol       Date:  2002-12       Impact factor: 5.103

4.  Human monoclonal antibodies that inhibit binding of hepatitis C virus E2 protein to CD81 and recognize conserved conformational epitopes.

Authors:  K G Hadlock; R E Lanford; S Perkins; J Rowe; Q Yang; S Levy; P Pileri; S Abrignani; S K Foung
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

5.  Amino acid changes at positions 173 and 187 in the human T-cell leukemia virus type 1 surface glycoprotein induce specific neutralizing antibodies.

Authors:  S Blanchard; T Astier-Gin; B Tallet; D Moynet; D Londos-Gagliardi; B Guillemain
Journal:  J Virol       Date:  1999-11       Impact factor: 5.103

6.  Human monoclonal antibody to hepatitis C virus E1 glycoprotein that blocks virus attachment and viral infectivity.

Authors:  Zhen-Yong Keck; Vicky M H Sung; Susan Perkins; Judy Rowe; Sudhir Paul; T Jake Liang; Michael M C Lai; Steven K H Foung
Journal:  J Virol       Date:  2004-07       Impact factor: 5.103

7.  The humoral immune response to human T-cell lymphotropic virus type 1 envelope glycoprotein gp46 is directed primarily against conformational epitopes.

Authors:  K G Hadlock; J Rowe; S K Foung
Journal:  J Virol       Date:  1999-02       Impact factor: 5.103

8.  DC-SIGN mediates cell-free infection and transmission of human T-cell lymphotropic virus type 1 by dendritic cells.

Authors:  Pooja Jain; Sharrón L Manuel; Zafar K Khan; Jaya Ahuja; Kevin Quann; Brian Wigdahl
Journal:  J Virol       Date:  2009-08-19       Impact factor: 5.103

Review 9.  Current status of HTLV-1 infection.

Authors:  Toshiki Watanabe
Journal:  Int J Hematol       Date:  2011-10-04       Impact factor: 2.319

10.  Immunogenic and functional organization of hepatitis C virus (HCV) glycoprotein E2 on infectious HCV virions.

Authors:  Zhen-Yong Keck; Jinming Xia; Zhaohui Cai; Ta-Kai Li; Ania M Owsianka; Arvind H Patel; Guangxiang Luo; Steven K H Foung
Journal:  J Virol       Date:  2006-11-01       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.